Alerts will be sent to your verified email
Verify EmailNEPHROPLUS
The thesis comes alive only if planned treatment-volume growth converts from new and acquired capacity; capacity additions alone do not create revenue in this fixed-capacity business.
Bull path depends on a faster treatment-volume ramp combined with a stronger revenue-per-treatment mix, while bear path is triggered by treatment-volume underperformance alongside stagnant revenue per treatment.
Key revision triggers to watch include quarterly treatment growth, revenue per treatment, clinic additions, and the Andhra Pradesh PPP renewal outcome.
Executive Snapshot:
Competitive Position: Wide Moat (Network Effects) — The platform holds a dominant liquidity advantage with 222K paying suppliers and 42M active buyers. However, the moat is Stable rather than widening. While network effects protect against new entrants, they are not currently driving new usage velocity at the bottom of the pyramid (Silver tier churn is high), indicating saturation or value-proposition mismatch for smaller SMEs.
| Scenario | Probability | Key Drivers |
|---|---|---|
| Base Case | 55-60% | Supplier base grows 3-4% CAGR; Revenue growth driven by 8-10% ARPU hikes; Margins stabilize ~35% due to reduced acquisition spend. |
| Bear Case | 25-30% | Elevated risk. Triggered if Standalone Collections growth stays <10% for 2 more quarters OR if entry-level churn forces price rollbacks. (See Section 5). |
| Bull Case | 15-20% | Requires specific breakout in 'Busy Infotech' scaling (>30% CAGR) AND successful stabilization of Silver bucket churn leading to >6K net adds/quarter. |
Base case probability is anchored by the persistent disconnect between management's aspiration (20%+ growth) and actual delivery (12% Consolidated Revenue growth in Q2 FY26). The Bear case is elevated above standard 20% because the core standalone engine shows signs of saturation (net additions were negative in Q3 FY25 and only modestly recovered to +2.8K in Q2 FY26).
Note: Base Year FY25 Actuals used. FY26 estimates annualized based on H1 FY26 actuals (Q1+Q2).
| Metric | FY25 (A) | FY26 (E) | FY27 (E) | FY28 (E) | FY29 (E) | FY30 (E) | CAGR |
|---|---|---|---|---|---|---|---|
| Revenue (Rs. Cr) | |||||||
| - Base Case (55-60%) | 1,388 | 1,585 | 1,805 | 2,055 | 2,340 | 2,665 | 13.7% |
| - Bear Case (25-30%) | – | 1,550 | 1,675 | 1,810 | 1,935 | 2,050 | 8.1% |
| - Bull Case (15-20%) | – | 1,620 | 1,945 | 2,330 | 2,800 | 3,360 | 19.3% |
| EBITDA (Rs. Cr) | |||||||
| - Base Case (55-60%) | 523 | 555 | 650 | 780 | 915 | 1,065 | 15.2% |
| - Bear Case (25-30%) | – | 535 | 550 | 580 | 600 | 615 | 3.8% |
| - Bull Case (15-20%) | – | 580 | 740 | 930 | 1,150 | 1,410 | 22.0% |
| EBITDA Margin | 37.7% | 35.0% | 36.0% | 38.0% | 39.1% | 40.0% | |
| PAT | 551 | 580 | 675 | 810 | 960 | 1,120 | 15.2% |
| PAT Margin | 39.7% | 36.6% | 37.4% | 39.4% | 41.0% | 42.0% | |
This section breaks down the total projected revenue increase (Base Case) into its component drivers.
ARPU Expansion & Tier Migration (~60% / Rs.648 Cr)
Net New Supplier Volume (~20% / Rs.216 Cr)
Accounting Software (Busy Infotech) (~15% / Rs.162 Cr)
Other Income/Adjacencies (~5% / Rs.54 Cr)
4.1 Revenue Growth Assumptions
4.2 Margin Trajectory Rationale
4.3 Key Risks to Estimates
4.4 Execution/Credibility Note
4.5 Data Limitations
Bear Case (FY30 Revenue Rs.2,050 Cr, 25-30% Prob):
Bull Case (FY30 Revenue Rs.3,360 Cr, 15-20% Prob):
Report is AI-generated and may contain inaccuracies. Analysis based on regulatory filings up to 2 hours prior to request.
|
Nephrocare Health
|
Narayana Hrudayalay.
|
Jupiter Life Line
|
|
|---|---|---|---|
|
|
|||
|
|
|||
|
Revenue Per Treatment
|
2733.0 Rs | n/a | n/a |
|
Annual Treatments
|
3.84 Million No | n/a | n/a |
|
|
|||
|
Total Number of Clinics
|
550.0 | n/a | n/a |
|
|
|||
|
|
6.71 % | 23.67 % | 15.88 % |
|
5yr average Equity Multiplier
|
1.63 | 2.16 | 1.97 |
|
5yr Average Asset Turnover Ratio
|
0.71 | 0.9 | 0.77 |
|
5yr Avg Net Profit Margin
|
5.02 % | 12.68 % | 11.9 % |
|
Price to Book
|
5.54 | 7.74 | 5.42 |
|
P/E
|
80.53 | 43.06 | 44.65 |
|
|
-88.44 Days | -159.28 Days | -82.26 Days |
|
Inventory Days
|
15.59 Days | 6.16 Days | 7.11 Days |
|
Days Receivable
|
106.58 Days | 27.99 Days | 14.45 Days |
|
Days Payable
|
153.09 Days | 192.98 Days | 126.63 Days |
|
5yr Average Interest Coverage Ratio
|
2.73 | 7.38 | 9.91 |
|
5yr Avg ROCE
|
10.32 % | 20.12 % | 16.79 % |
|
5yr Avg Operating Profit Margin
|
18.43 % | 21.47 % | 22.37 % |
|
5 yr average Debt to Equity
|
0.38 | 0.58 | 0.71 |
|
5yr CAGR Net Profit
|
n/a | 18.68 % | 30.57 % |
|
5yr Average Return on Assets
|
3.73 % | 11.33 % | 9.04 % |
|
|
|||
|
Promoter Holding
|
63.85 % | 63.27 % | 40.91 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -0.58 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
-0.24 % | -1.74 % | 1.88 % |
|
Nephrocare Health
|
Narayana Hrudayalay.
|
Jupiter Life Line
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|